Should biologics for psoriasis be interrupted in the era of COVID-19?

Authors :: Lebwohl M
Rivera-Oyola R
Murrell DF
Source :: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2020 May; Vol. 82 (5), pp. 1217-1218. Date of Electronic Publication: 2020 Mar 19.
Publication Year :: 2020

Subjects :: Betacoronavirus
Biological Products therapeutic use
COVID-19
Humans
Nasopharyngitis complications
Pandemics
Psoriasis complications
Respiratory Tract Infections complications
Risk Factors
SARS-CoV-2
Tumor Necrosis Factor-alpha antagonists & inhibitors
Biological Products administration & dosage
Coronavirus Infections complications
Pneumonia, Viral complications
Psoriasis drug therapy

Full Text Access

Tools